CRISPR Therapeutics Reports Q2 2025 Revenue Surge to $892K, Net Loss of $208.5M

CRISPR Therapeutics AG reported its financial results for the second quarter of 2025, revealing a total revenue of $892,517, a significant increase from $1,757 in the same period last year. For the first half of 2025, the company generated $1,757 in revenue, compared to $1,021 in the first half of 2024. The revenue primarily stemmed from grant income, as the company has not yet generated revenue from product sales. However, the company incurred a net loss of $208.5 million for the second quarter, compared to a loss of $126.4 million in the same quarter of 2024. For the first half of 2025, the net loss was $344.5 million, up from $243.0 million in the prior year.

Operating expenses for the second quarter totaled $230.2 million, a notable increase from $151.8 million in the same quarter of 2024. This rise was largely attributed to a $96.3 million expense related to acquired in-process research and development, following the company's collaboration agreement with Sirius Therapeutics. Research and development expenses decreased to $69.9 million from $80.2 million year-over-year, while general and administrative expenses slightly declined to $18.9 million from $19.5 million. The collaboration expense, net, also decreased to $45.2 million from $52.1 million, reflecting a reduction in operating costs associated with the CASGEVY program.

In terms of operational metrics, CRISPR Therapeutics reported a total cash, cash equivalents, and marketable securities balance of $1.7 billion as of June 30, 2025, down from $2.2 billion at the end of 2024. The company’s accumulated deficit increased to $1.7 billion, reflecting ongoing investments in research and development. The company’s employee headcount remained stable, with no significant changes reported in staffing levels.

Strategically, CRISPR Therapeutics has made significant advancements, including the successful launch of CASGEVY, the first CRISPR-based therapy approved for use. The company is also actively pursuing collaborations, such as the recent agreement with Sirius Therapeutics, which involves joint development and commercialization of siRNA therapies. The company continues to explore additional partnerships to enhance its research capabilities and expand its product pipeline.

Looking ahead, CRISPR Therapeutics anticipates continued investment in its research and development programs, with expectations of incurring losses for the foreseeable future. The company believes its existing cash reserves will support operations for at least the next 24 months, although it may seek additional financing to support long-term clinical development and commercialization efforts. The outlook remains contingent on the successful progression of its clinical trials and the potential for future revenue generation from its product candidates.